• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

治疗性血浆置换在COVID-19患者治疗中的潜力：免疫发病机制与凝血病

Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.

作者信息

Balagholi Sahar, Dabbaghi Rasul, Eshghi Peyman, Mousavi Seyed Asadollah, Heshmati Farhad, Mohammadi Saeed

机构信息

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Ophtalmic Research Center, Research Institute for Ophtalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Transfus Apher Sci. 2020 Dec;59(6):102993. doi: 10.1016/j.transci.2020.102993. Epub 2020 Nov 2.

DOI:10.1016/j.transci.2020.102993
PMID:33162341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7605792/
Abstract

Therapeutic plasmapheresis (TP) is the process of the separation and removal of plasma from other blood components and is considered as an adjunctive treatment strategy to the discarded abnormal agent in the management of respiratory viral pandemics. This article reviews the mechanisms of immunopathogenesis and coagulopathy induced by SARS-CoV-2 and the potential benefits of TP as adjunctive treatment in critically COVID-19 patients.

摘要

治疗性血浆置换（TP）是从其他血液成分中分离并去除血浆的过程，在呼吸道病毒大流行的管理中被视为一种辅助治疗策略，用于清除废弃的异常物质。本文综述了SARS-CoV-2诱导的免疫发病机制和凝血病，以及TP作为重症COVID-19患者辅助治疗的潜在益处。

相似文献

1
Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.治疗性血浆置换在COVID-19患者治疗中的潜力：免疫发病机制与凝血病
Transfus Apher Sci. 2020 Dec;59(6):102993. doi: 10.1016/j.transci.2020.102993. Epub 2020 Nov 2.
2
Transfusion requirements in patients with COVID-19.新型冠状病毒肺炎患者的输血需求
Eur J Haematol. 2021 Jan;106(1):132-134. doi: 10.1111/ejh.13521. Epub 2020 Oct 9.
3
The successful management of an elderly Covid-19 infected patient by plasmapheresis.通过血浆置换成功治疗一名感染新冠病毒的老年患者。
Transfus Apher Sci. 2020 Dec;59(6):102924. doi: 10.1016/j.transci.2020.102924. Epub 2020 Aug 25.
4
[Coagulopathy and COVID-19. Recommendations for a changing reality].[凝血功能障碍与2019冠状病毒病。应对不断变化的现实的建议]
Medicina (B Aires). 2020;80(5):505-511.
5
Multisystem Assessment of the Imaging Manifestations of Coagulopathy in Hospitalized Patients With Coronavirus Disease (COVID-19).住院 COVID-19 患者凝血异常的影像学表现的多系统评估。
AJR Am J Roentgenol. 2021 Apr;216(4):1088-1098. doi: 10.2214/AJR.20.24132. Epub 2021 Feb 3.
6
Thrombosis and Coagulopathy in COVID-19.新型冠状病毒肺炎中的血栓与出凝血障碍。
Curr Probl Cardiol. 2021 Mar;46(3):100742. doi: 10.1016/j.cpcardiol.2020.100742. Epub 2020 Nov 2.
7
Large sacral/buttocks ulcerations in the setting of coagulopathy: A case series establishing the skin as a target organ of significant damage and potential morbidity in patients with severe COVID-19.凝血功能障碍背景下的大型骶部/臀部溃疡：一项病例系列研究，证实皮肤是重症 COVID-19 患者重要的受损靶器官及潜在发病部位。
Int Wound J. 2020 Dec;17(6):2033-2037. doi: 10.1111/iwj.13457. Epub 2020 Aug 7.
8
The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19.抗血小板药物在新型冠状病毒肺炎动脉血栓预防中的应用。
Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):114-115. doi: 10.1016/j.rec.2020.08.009. Epub 2020 Aug 28.
9
An 89-Year-Old Man with COVID-19-Associated Coagulopathy Presenting with a Prolonged Partial Thromboplastin Time, Lupus Anticoagulant, and a High Titer of Factor VIII Inhibitor.一名89岁患有新冠病毒相关凝血病的男性，表现为部分凝血活酶时间延长、狼疮抗凝物及高滴度的凝血因子VIII抑制物。
Am J Case Rep. 2020 Oct 30;21:e926728. doi: 10.12659/AJCR.926728.
10
Extrapulmonary SARS-CoV-2 manifestations.新型冠状病毒肺炎的肺外表现
Nat Med. 2020 Dec;26(12):1806. doi: 10.1038/s41591-020-01162-z.

引用本文的文献

1
Early plasmapheresis in type 2 benign recurrent intrahepatic cholestasis: A case report and review of literature.2型良性复发性肝内胆汁淤积症的早期血浆置换：一例病例报告及文献综述
World J Hepatol. 2025 Feb 27;17(2):102375. doi: 10.4254/wjh.v17.i2.102375.
2
The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges.2019冠状病毒病中炎症与血栓形成的相互作用：机制、治疗策略及挑战
Thromb Update. 2022 Aug;8:100117. doi: 10.1016/j.tru.2022.100117. Epub 2022 Jul 9.
3
The Impact of Therapeutic Plasma Exchange on Inflammatory Markers and Acute Phase Reactants in Patients with Severe SARS-CoV-2 Infection.治疗性血浆置换对重症 SARS-CoV-2 感染患者炎症标志物和急性期反应物的影响。
Medicina (Kaunas). 2023 Apr 29;59(5):867. doi: 10.3390/medicina59050867.
4
Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection.血浆置换对因严重COVID-19感染而发生细胞因子风暴的中性粒细胞减少患者的疗效。
Blood Res. 2023 Jun 30;58(2):91-98. doi: 10.5045/br.2023.2022201. Epub 2023 May 10.
5
Assessing the Outcomes of Patients with Severe SARS-CoV-2 Infection after Therapeutic Plasma Exchange by Number of TPE Sessions.根据治疗性血浆置换（TPE）疗程数量评估重症新型冠状病毒2型（SARS-CoV-2）感染患者的治疗结果。
J Clin Med. 2023 Feb 22;12(5):1743. doi: 10.3390/jcm12051743.
6
Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on "Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. 2022, , 860".回复巴雷耶等人。旧一代粘弹性检测方法是否已准备好被淘汰？评“沃洛德等人。粘弹性止血检测：传统与新一代设备入门。2022年，，860”。
J Clin Med. 2023 Jan 6;12(2):478. doi: 10.3390/jcm12020478.
7
Comparison of the Effects of Plasmapheresis, Hemoperfusion, and Convalescent Plasma Therapy on Inflammatory Factors in COVID-19 Patients.血浆置换、血液灌流和恢复期血浆治疗对COVID-19患者炎症因子影响的比较
Med J Islam Repub Iran. 2022 Nov 26;36:142. doi: 10.47176/mjiri.36.142. eCollection 2022.
8
Effectiveness of Plasmapheresis Treatment in the Treatment of Patients with COVID-19 Disease.血浆置换疗法在治疗新型冠状病毒肺炎患者中的有效性
Med J Islam Repub Iran. 2022 Jul 25;36:83. doi: 10.47176/mjiri.36.83. eCollection 2022.
9
The Successful Recovery of a Critically Ill COVID-19 Patient, Following the Combination of Therapeutic Plasma Exchange and Convalescent Plasma Transfusion: A Case Report.《COVID-19 危重症患者接受治疗性血浆置换联合恢复期血浆输注后成功康复：一例报告》。
Medicina (Kaunas). 2022 Aug 12;58(8):1088. doi: 10.3390/medicina58081088.
10
The association between SARS-CoV-2 vaccines and transverse myelitis: A review.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗与横贯性脊髓炎之间的关联：一项综述
Ann Med Surg (Lond). 2022 Jun 9;79:103870. doi: 10.1016/j.amsu.2022.103870. eCollection 2022 Jul.

本文引用的文献

1
Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19.血浆置换和免疫球蛋白替代疗法（静脉注射免疫球蛋白）对新冠肺炎患者的疗效
SN Compr Clin Med. 2020;2(9):1407-1411. doi: 10.1007/s42399-020-00438-2. Epub 2020 Jul 31.
2
Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.治疗性血浆置换：危重症COVID-19患者的一种潜在管理策略。
J Intensive Care Med. 2020 Sep;35(9):827-835. doi: 10.1177/0885066620940259. Epub 2020 Jul 15.
3
Cytokine Storms: Understanding COVID-19.细胞因子风暴：了解 COVID-19。
Immunity. 2020 Jul 14;53(1):19-25. doi: 10.1016/j.immuni.2020.06.017. Epub 2020 Jun 28.
4
The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.治疗性血浆置换在伴有多器官功能衰竭的重症新型冠状病毒肺炎急性呼吸窘迫综合征中的成功应用。
SAGE Open Med Case Rep. 2020 Jun 18;8:2050313X20933473. doi: 10.1177/2050313X20933473. eCollection 2020.
5
Therapeutic plasma exchange in adults with severe COVID-19 infection.成人严重 COVID-19 感染的治疗性血浆置换。
Int J Infect Dis. 2020 Oct;99:214-218. doi: 10.1016/j.ijid.2020.06.064. Epub 2020 Jun 23.
6
Application of plasmapheresis for Covid-19 patients.血浆置换在新冠肺炎患者中的应用。
Ther Apher Dial. 2021 Apr;25(2):248-249. doi: 10.1111/1744-9987.13536. Epub 2020 Jul 11.
7
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.COVID-19 中的细胞因子风暴：发病机制和治疗中使用的抗炎药物概述。
Clin Rheumatol. 2020 Jul;39(7):2085-2094. doi: 10.1007/s10067-020-05190-5. Epub 2020 May 30.
8
The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.COVID-19 中的细胞因子风暴：趋化因子/趋化因子受体系统的参与概述。
Cytokine Growth Factor Rev. 2020 Jun;53:25-32. doi: 10.1016/j.cytogfr.2020.05.003. Epub 2020 May 11.
9
[Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].6例接受血浆置换或托珠单抗治疗的重症新型冠状病毒肺炎患者的临床观察
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):227-231. doi: 10.3785/j.issn.1008-9292.2020.03.06.
10
Expert recommendations on blood purification treatment protocol for patients with severe COVID-19.针对重症新型冠状病毒肺炎患者血液净化治疗方案的专家建议。
Chronic Dis Transl Med. 2020 Apr 28;6(2):106-114. doi: 10.1016/j.cdtm.2020.04.002. eCollection 2020 Jun.